Here are some key takeaways from the Closing Session:

“I want us all at the finishing line,” highlighted Dame Sally in her keynote speech, reminding us all that with the continuing AMR crisis #wearethelobster slowly getting boiled unless we act together now.

“Europe has to step up and set up a pan-European strategy to incentivize innovation in AMR product development and commercialization,” said Marc Gitzinger on behalf of BEAM Alliance, referring to a post conference papersupported by further stakeholders such as NOVO REPAIR IMPACT FUND, GARDP, the Antimicrobials Working Group, the BIO organisation, IFPMA and Pfizer and more.

“Policy needs to put legislation on the table,” urged Tiemo Woelken from the European Parliament MEP Interest Group on AMR. He is also calling for the EU commission to put AMR on the agenda of the European pharmaceutical strategy which is currently discussed.

“Our problem can’t be solved by a country-by-country basis. This takes too much time. Joint action in Europe is needed,” said Evan Loh, CEO Paratek and representing the Antimicrobial Working Group in the US.

“AMR is a hidden pandemic and COVID-19 has shown us that political will can drive innovation.”

Play Video

What you can expect

The AMR Conference is a platform to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to market.

More than 400 participants from 25+ countries

High-level panels and expert sessions > live and on-demand

Scientific poster presentations

A wide variety of topics from financing, development & regulation

Virtual 1:1 partnering meetings

SMEs, academics & governmental agencies benefit from discounted fees

2019 Event Highlights

Event Impressions & Testimonials

More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR). The AMR Conference is a platform for SMEs, start-ups, big pharma, academia, clinicians, investors, public stakeholders and policy-makers to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market.

see all highlights